Loading ZTS detail
Loading ticker data...
Loading ZTS detail
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Chart data unavailable
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Douglas Lane and Associates LLC grew its position in Zoetis Inc. (NYSE: ZTS) by 30.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 401,246 shares of the company's stock after buying an additional 94,493 shares during the period. Douglas Lane and Associates LLC
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CCLA Investment Management reduced its stake in Zoetis Inc. (NYSE: ZTS) by 1.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 885,388 shares of the company's stock after selling 13,213 shares during the period. CCLA Investment Management owned
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The April 2026 Top 25 High Growth Dividend Stocks list targets quality companies trading below intrinsic value, averaging a 1.52% yield and 17.7% five-year dividend growth. Screened stocks appear ~34% undervalued by dividend yield theory, with an estimated +21% annualized long-term return potential. MSCI, WING, ZTS, INTU, and MSFT stand out for attractive valuations, robust dividend growth, and strong projected EPS growth.
Ascent Group LLC reduced its stake in Zoetis Inc. (NYSE: ZTS) by 31.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 12,563 shares of the company's stock after selling 5,676 shares during the quarter. Ascent Group LLC's holdings in Zoetis were worth
Nvwm LLC trimmed its holdings in Zoetis Inc. (NYSE: ZTS) by 85.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,063 shares of the company's stock after selling 11,712 shares during the quarter. Nvwm LLC's holdings in Zoetis were worth $260,000 at
McBroom and Associates LLC lowered its position in shares of Zoetis Inc. (NYSE: ZTS) by 72.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,849 shares of the company's stock after selling 21,006 shares during the quarter. McBroom and Associates LLC's
Zoetis offers broad diversification across hundreds of animal health products, with nearly equal U.S. and international revenue exposure. ZTS posted resilient Q4 2025 results, with 3% revenue growth, 5.7% EPS growth, and a robust 27%+ non-GAAP net margin, outperforming consensus. Key 2026 catalysts include launches of next-generation osteoarthritis drugs Portela and Lenivia, targeting improved compliance and expanded market reach.
Aberdeen Group plc boosted its stake in shares of Zoetis Inc. (NYSE: ZTS) by 7.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,188,371 shares of the company's stock after purchasing an additional 79,220 shares during the period. Aberdeen
Zoetis Inc. (ZTS) is rated a hold, as shares trade near fair value with limited upside despite sector leadership and defensive qualities. The company guides for 3-5% organic operational growth in 2026 and remains very shareholder-friendly, reflected in a 20% 5-year DPS growth and 6.6% buyback yield. Zoetis faces risks from pipeline concentration, potential margin pressure due to increasing competition and product setbacks, notably Librela's 32% sales decline due to safety concerns.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-pr.
Exchange Traded Concepts LLC increased its stake in shares of Zoetis Inc. (NYSE: ZTS) by 55.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,994 shares of the company's stock after acquiring an additional 4,266 shares during the
Compagnie Lombard Odier SCmA lowered its stake in shares of Zoetis Inc. (NYSE: ZTS) by 25.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,215 shares of the company's stock after selling 4,396 shares during the period.
